All News

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Data from the phase 3 DESTINY-Breast06 trial were presented during the 2024 San Antonio Breast Cancer Symposium.

I haven’t been too happy with my blood work with CLL, but I try to enjoy what I can — including apples during fall.

Findings from the phase 1 SERENA-1 study were presented at the 2024 San Antonio Breast Cancer Symposium.

Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients with previously treated CLL or SLL.

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant setting with early breast cancer.

Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.

Setbacks happen often in life, but finding gratitude can come at unexpected moments with cancer.

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary refractory patients.

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

Patients with treatment-naive CLL/SLL experienced long-term improved efficacy when treated with Brukinsa compared with bendamustine plus Rituxan.

Adding pelabresib to a JAK inhibitor may improve multiple aspects of myelofibrosis, including spleen size, symptoms and bone marrow fibrosis.

One year, after breast cancer treatment, I decided to have a Christmas photoshoot with my family, which turned out to be a good laugh in the end.

Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates.

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.

Maggie Bushway reflected on her memoir “Pearls: A Memoir on Childhood Cancer and Hope,” and her journey of healing and resilience after brain cancer.

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in patients with chronic myeloid leukemia.

Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.

Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival.

Results from the study also showed the potential association between smoking, disease progression and survival in patients with myelodysplastic syndromes.

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.

Pediatric patients with standard-risk B-ALL demonstrated significantly improved disease-free survival with Blincyto plus chemotherapy versus chemotherapy alone.

CURE celebrated seven MPN Heroes, who ranged from patients to medical professionals, on the contributions they made in the community.

Treatment with five-fraction SBRT could be effective versus traditional radiation in certain patients with low- or intermediate-risk prostate cancer.

Since 2000, antibody-drug conjugates have been approved by the Food and Drug Administration for various cancer types, such as breast cancer.